Sydney, Jan 18, 2026, 17:19 AEDT — Market closed.
- CSL shares last closed at A$175.53 on Friday, up 0.14%.
- The company is due to report half-year results and set its interim dividend on Feb. 11.
- The Seqirus vaccines outlook remains a swing factor after CSL cut FY26 growth guidance in October.
CSL Limited ASX:CSL shares last closed at A$175.53 on Friday, up A$0.25, or 0.14%, as the stock held its ground heading into a market-closed weekend.
The next big move may not come from the tape. CSL has been trying to rebuild credibility since it cut its fiscal 2026 growth outlook in October and shelved plans to spin off its Seqirus vaccines unit, after a sharper-than-expected slide in U.S. influenza vaccinations. CEO Paul McKenzie said Seqirus had seen “a greater decline” in U.S. vaccination rates “than we expected.” Reuters
With Australia’s market shut on Sunday, traders head into Monday with the next set-piece already pencilled in: CSL’s half-year results and interim dividend announcement on Feb. 11. Shares are scheduled to trade ex-dividend on March 10, with a March 11 record date for the interim payout.
On Friday, CSL traded between A$174.35 and A$176.07. About 1 million shares changed hands, Yahoo Finance data showed.
The longer arc still matters. CSL last year laid out a restructure that included cutting its workforce by up to 15% and resuming an on-market buyback, targeting A$750 million in repurchases in fiscal 2026. It also flagged annualised savings of $500 million to $550 million over three years, alongside a one-off pre-tax charge of $700 million to $770 million tied to the initiatives.
For investors, the list is familiar and not short. They want cleaner numbers out of the core plasma-derived therapies business, and a more stable read on Seqirus after the U.S. flu season wobble forced CSL to reset its targets.
They will also watch for any shift in tone on the Seqirus separation, which CSL has said depends on market conditions, and for clues on how much of the planned savings are landing — and when.
But it can still go sideways. A weaker U.S. flu season than management is building in could keep pressure on Seqirus volumes and pricing, and that would risk another round of guidance trimming at a time when the stock is trying to form a base.
CSL resumes trade on Monday, Jan. 19. The next hard catalyst is the Feb. 11 half-year result and interim dividend decision, which is likely to set the tone for the stock into March.
